open access

Vol 12, No 1 (2017)
Review Papers
Published online: 2017-01-29
Get Citation

Atherogenic dyslipidemia in everyday practice — interdisciplinary consensus of Polish experts

Filip Szymański, Krzysztof J. Filipiak, Beata Wożakowska-Kapłon, Jacek P. Szaflik, Grzegorz Dzida, Iwona Kurkowska-Jastrzębska, Krzysztof Narkiewicz, Monika Łazicka-Gałecka, Robert J. Gil, Janusz Gumprecht
DOI: 10.5603/FC.a2016.0106
·
Folia Cardiologica 2017;12(1):33-49.

open access

Vol 12, No 1 (2017)
Review Papers
Published online: 2017-01-29

Abstract

Dyslipidemia is the most common risk factor for cardiovascular diseases in Poland. According to the latest guidelines of Scientific Societies, the primary goal of lipid-lowering therapy is to lower LDL-cholesterol, but we should not underestimate the impact of atherogenic dyslipidemia, defined as elevated levels of triglycerides (TG) and very-low-density lipoprotein (VLDL) and decreased HDL-cholesterol (HDL-C), on the progression of atherosclerosis. High TG and low HDL-C are independent risk factors for cardiovascular events, which can be effectively monitored and treated with statins and fenofibrate. The following consensus statement of Polish experts is an attempt to summarize the latest knowledge in the field of atherogenic dyslipidemia and to develop the recommendations for its treatment.

Abstract

Dyslipidemia is the most common risk factor for cardiovascular diseases in Poland. According to the latest guidelines of Scientific Societies, the primary goal of lipid-lowering therapy is to lower LDL-cholesterol, but we should not underestimate the impact of atherogenic dyslipidemia, defined as elevated levels of triglycerides (TG) and very-low-density lipoprotein (VLDL) and decreased HDL-cholesterol (HDL-C), on the progression of atherosclerosis. High TG and low HDL-C are independent risk factors for cardiovascular events, which can be effectively monitored and treated with statins and fenofibrate. The following consensus statement of Polish experts is an attempt to summarize the latest knowledge in the field of atherogenic dyslipidemia and to develop the recommendations for its treatment.

Get Citation

Keywords

atherogenic dyslipidaemia, expert consensus, cardiovascular risk

About this article
Title

Atherogenic dyslipidemia in everyday practice — interdisciplinary consensus of Polish experts

Journal

Folia Cardiologica

Issue

Vol 12, No 1 (2017)

Pages

33-49

Published online

2017-01-29

DOI

10.5603/FC.a2016.0106

Bibliographic record

Folia Cardiologica 2017;12(1):33-49.

Keywords

atherogenic dyslipidaemia
expert consensus
cardiovascular risk

Authors

Filip Szymański
Krzysztof J. Filipiak
Beata Wożakowska-Kapłon
Jacek P. Szaflik
Grzegorz Dzida
Iwona Kurkowska-Jastrzębska
Krzysztof Narkiewicz
Monika Łazicka-Gałecka
Robert J. Gil
Janusz Gumprecht

References (79)
  1. Catapano AL, Graham I, De Backer G. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016; 253: 281–344.
  2. Piepoli MF, Hoes AW, Agewall S, et al. Authors/Task Force Members:, Authors/Task Force Members, Additional Contributor: Simone Binno (Italy), Document Reviewers:, Authors/Task Force Members. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016; 37(29): 2315–2381.
  3. Leiter LA, Lundman P, da Silva PM, et al. DYSIS investigators. Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. Diabet Med. 2011; 28(11): 1343–1351.
  4. Zdrojewski T, Solnica B, Cybulska B, et al. Prevalence of lipid abnormalities in Poland. The NATPOL 2011 survey. Kardiol Pol. 2016; 74(3): 213–223.
  5. de la Sierra A, Gorostidi M, Aranda P, et al. Prevalence of Atherogenic Dyslipidemia in Spanish Hypertensive Patients and Its Relationship With Blood Pressure Control and Silent Organ Damage. Rev Esp Cardiol (Engl Ed). 2015; 68(7): 592–598.
  6. Toth PP, Barter PJ, Rosenson RS, et al. High-density lipoproteins: a consensus statement from the National Lipid Association. J Clin Lipidol. 2013; 7(5): 484–525.
  7. Robinson JG, Wang S, Smith BJ, et al. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol. 2009; 53(4): 316–322.
  8. Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012; 307(12): 1302–1309.
  9. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996; 3(2): 213–219.
  10. Faergeman O, Holme I, Fayyad R, et al. Steering Committees of IDEAL and TNT Trials. Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease. Am J Cardiol. 2009; 104(4): 459–463.
  11. Miller M, Cannon CP, Murphy SA, et al. PROVE IT-TIMI 22 Investigators. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008; 51(7): 724–730.
  12. Assmann G, Cullen P, Schulte H. The Münster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J. 1998; 19 Suppl A: A2–11.
  13. Barter P, Gotto AM, LaRosa JC, et al. Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007; 357(13): 1301–1310.
  14. Retnakaran R, Cull CA, Thorne KI, et al. UKPDS Study Group. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes. 2006; 55(6): 1832–1839.
  15. Colhoun HM, Betteridge DJ, Durrington PN, et al. CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004; 364(9435): 685–696.
  16. Buse JB, Bigger JT, Byington RP. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol. 2007; 99(12A): 21i–31i.
  17. Ginsberg HN, Elam MB, Lovato LC, et al. ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010; 362(17): 1563–1574.
  18. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) Study. Circulation. 2000; 102(1): 21–27.
  19. Arbel Y, Klempfner R, Erez A, et al. BIP Study Group. Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial. Cardiovasc Diabetol. 2016; 15: 11.
  20. Lyons TJ, Jenkins AJ, Zheng D. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci. 2004; 45(3): 910–918.
  21. Keech A, Simes RJ, Barter P, et al. FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study) Lancet. 2005; 366: 1840–1861.
  22. Ansquer JC, Foucher C, Rattier S, et al. DAIS Investigators. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis. 2005; 45(3): 485–493.
  23. Chew EY, Ambrosius WT, Davis MD, et al. ACCORD Study Group, ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010; 363(3): 233–244.
  24. Catapano AL, Graham I, De Backer B, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2016; 37(39): 2999–3058.
  25. Wożakowska-Kapłon B, Filipiak KJ, Mamcarz A, et al. [Actual problems of dyslipidaemia treatment in Poland - 2nd Declaration of Sopot. Experts' Group Consensus endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy]. Kardiol Pol. 2014; 72(9): 847–853.
  26. Cannon CP, Blazing MA, Giugliano RP, et al. IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015; 372(25): 2387–2397.
  27. Miller M, Cannon CP, Murphy SA, et al. PROVE IT-TIMI 22 Investigators. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008; 51(7): 724–730.
  28. Yun KHo, Shin IS, Rhee SJ, et al. Clinical significance of on-treatment triglyceride level in patients treated by percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome. Korean J Intern Med. 2009; 24(4): 330–336.
  29. Schwartz GG, Abt M, Bao W, et al. Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. J Am Coll Cardiol. 2015; 65(21): 2267–2275.
  30. Buturak A, Degirmencioglu A, Erturk M, et al. Impact of increased admission lipid levels on periprocedural myocardial injury following an elective percutaneous coronary intervention. Coron Artery Dis. 2015; 26(4): 333–340.
  31. Shah HD, Parikh KH, Chag MC, et al. Beneficial effects of the addition of fenofibrate to statin therapy in patients with acute coronary syndrome after percutaneous coronary interventions. Exp Clin Cardiol. 2007; 12(2): 91–96.
  32. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. The Lancet. 2008; 371(9607): 117–125.
  33. Fruchart JC, Sacks FM, Hermans MP, et al. Residual Risk Reduction Initiative (R3I). The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res. 2008; 5(4): 319–335.
  34. Guy J, Ogden L, Wadwa RP, et al. Lipid and lipoprotein profiles in youth with and without type 1 diabetes: the SEARCH for Diabetes in Youth case-control study. Diabetes Care. 2009; 32(3): 416–420.
  35. Robinson JG, Wang S, Smith BJ, et al. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol. 2009; 53(4): 316–322.
  36. Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010; 375(9729): 1875–1884.
  37. Jun M, Zhu B, Tonelli M, et al. Effects of fibrates in kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol. 2012; 60(20): 2061–2071.
  38. Ginsberg HN, Elam MB, Lovato LC, et al. ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010; 362(17): 1563–1574.
  39. Mychaleckyj JC, Craven T, Nayak U, et al. Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care. 2012; 35(5): 1008–1014.
  40. Ting RD, Keech AC, Drury PL, et al. FIELD Study Investigators. Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study. Diabetes Care. 2012; 35(2): 218–225.
  41. Davis TM, Ting R, Best JD, et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia. 2011; 54(2): 280–290.
  42. Udani SM, Bakris GL. Do fibrates truly preserve kidney function? Nat Rev Endocrinol. 2011; 7(3): 130–131.
  43. Niewada M, Skowrońska M, Ryglewicz D, et al. Polish National Stroke Prevention and Treatment Collaborative Group. Acute ischemic stroke care and outcome in centers participating in the Polish National Stroke Prevention and Treatment Registry. Stroke. 2006; 37(7): 1837–1843.
  44. Sacco RL, Benjamin EJ, Broderick JP, et al. American Heart Association Prevention Conference. IV. Prevention and Rehabilitation of Stroke. Risk factors. Stroke. 1997; 28(7): 1507–1517.
  45. González-García S, González-Quevedo A, Fernández-Concepción O, et al. Gonzales-Quevedo Monteagudo A, Zuaznabar MAB. Association between blodd lipids and types of strokes. MEDICC Review. 2008; 10: 27–32.
  46. Iso H, Jacobs DR, Wentworth D, et al. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med. 1989; 320(14): 904–910.
  47. Collins R, Armitage J, Parish S, et al. Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004; 363(9411): 757–767.
  48. Amarenco P, Bogousslavsky J, Callahan A, et al. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006; 355(6): 549–559.
  49. Amarenco P, Labreuche J, Lavallée P, et al. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke. 2004; 35(12): 2902–2909.
  50. O'Donnell MJ, Chin SL, Rangarajan S, et al. INTERSTROKE investigators, INTERSTROKE investigators. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010; 376(9735): 112–123.
  51. Sacco RL, Benson RT, Kargman DE, et al. High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study. JAMA. 2001; 285(21): 2729–2735.
  52. Pikula A, Beiser AS, Wang J, et al. Lipid and lipoprotein measurements and the risk of ischemic vascular events: Framingham Study. Neurology. 2015; 84(5): 472–479.
  53. Zhu S, Su G, Meng QH. Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension. Clin Chem. 2006; 52(11): 2036–2042.
  54. Schwartz GG, Abt M, Bao W, et al. Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. J Am Coll Cardiol. 2015; 65(21): 2267–2275.
  55. Alpérovitch A, Kurth T, Bertrand M, et al. Primary prevention with lipid lowering drugs and long term risk of vascular events in older people: population based cohort study. BMJ. 2015; 350: h2335.
  56. Ouk T, Gautier S, Pétrault M, et al. Effects of the PPAR-α agonist fenofibrate on acute and short-term consequences of brain ischemia. J Cereb Blood Flow Metab. 2014; 34(3): 542–551.
  57. Zhou YH, Ye XF, Yu FF, et al. Lipid management in the prevention of stroke: a meta-analysis of fibrates for stroke prevention. BMC Neurol. 2013; 13: 1.
  58. Wang D, Liu B, Tao W, et al. Fibrates for secondary prevention of cardiovascular disease and stroke. Cochrane Database Syst Rev. 2015(10): CD009580.
  59. Davis TME, Yeap BB, Davis WA, et al. Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study. Diabetologia. 2008; 51(4): 562–566.
  60. Cho YeR, Lim JiH, Kim MY, et al. Therapeutic effects of fenofibrate on diabetic peripheral neuropathy by improving endothelial and neural survival in db/db mice. PLoS One. 2014; 9(1): e83204.
  61. Othman A, Benghozi R, Alecu I, et al. Fenofibrate lowers atypical sphingolipids in plasma of dyslipidemic patients: A novel approach for treating diabetic neuropathy? J Clin Lipidol. 2015; 9(4): 568–575.
  62. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998; 317(7160): 703–713.
  63. Scott R, O'Brien R, Fulcher G, et al. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care. 2009; 32(3): 493–498.
  64. Ginsberg HN, Elam MB, Lovato LC, et al. ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010; 362(17): 1563–1574.
  65. Stanowisko Polskiego Towarzystwa Diabetologicznego „Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2016” . Diabetol Klin. 2016; 5(supl. A): A1–A76.
  66. Li W, Yanoff M, Liu X, et al. Retinal capillary pericyte apoptosis in early human diabetic retinopathy. Chin Med J (Engl). 1997; 110(9): 659–663.
  67. Ejaz S, Chekarova I, Ejaz A, et al. Importance of pericytes and mechanisms of pericyte loss during diabetes retinopathy. Diabetes Obes Metab. 2008; 10(1): 53–63.
  68. Ding J, Wong TY. Current epidemiology of diabetic retinopathy and diabetic macular edema. Curr Diab Rep. 2012; 12(4): 346–354.
  69. Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol. 2007; 14(4): 179–183.
  70. King P, Peacock I, Donnelly R. The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol. 1999; 48(5): 643–648.
  71. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993; 329(14): 977–986.
  72. Schrier RW, Estacio RO, Mehler PS, et al. Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial. Nat Clin Pract Nephrol. 2007; 3(8): 428–438.
  73. Bosomworth NJ. Approach to identifying and managing atherogenic dyslipidemia: a metabolic consequence of obesity and diabetes. Can Fam Physician. 2013; 59(11): 1169–1180.
  74. Chew EY, Ambrosius WT, Davis MD, et al. ACCORD Study Group, ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010; 363(3): 233–244.
  75. Noonan JE, Jenkins AJ, Ma JX, et al. An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes. Diabetes. 2013; 62(12): 3968–3975.
  76. Stanowisko Polskiego Towarzystwa Diabetologicznego „Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2016”. Diabetol Klin. 2016; 5(supl. A): A1–A76.
  77. Rydén L, Grant PJ, Anker SD, et al. Authors/Task Force Members, ESC Committee for Practice Guidelines (CPG), Document Reviewers. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013; 34(39): 3035–3087.
  78. Wożakowska-Kapłon B, Filipiak K, Mamcarz A, et al. [Actual problems of dyslipidaemia treatment in Poland - 2nd Declaration of Sopot. Experts' Group Consensus endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy]. [Article in Polish]. Kardiol Pol. 2014; 72(9): 847–853.
  79. Aguiar C, Alegria E, Bonadonna RC, et al. A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy. Atheroscler Suppl. 2015; 19: 1–12.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl